Literature DB >> 20676949

[New drugs for the treatment of constipation].

Birgit Adam1, Tobias Liebregts, Guido Gerken.   

Abstract

This review introduces new therapeutic options in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Therefore, prucalopride and lubiprostone are discussed including their mechanisms and side effects. In addition, other substances that are currently under evaluation such as renzapride and linaclotide are described, since recent results showed a significant effect in patients with constipation. Thus, after the withdrawal of tegaserod due to cardiac side effects, new potent drugs are now available for the treatment of constipation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20676949     DOI： 10.1007/s00063-010-1081-z

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


  33 in total

1.  The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.

Authors:  N L Meyers; R I Hickling
Journal:  J Int Med Res       Date:  2007 Nov-Dec       Impact factor: 1.671

2.  Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.

Authors:  E P Bouras; M Camilleri; D D Burton; S McKinzie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  Safety of domperidone in metoclopramide-induced parkinsonism.

Authors:  J D Grimes; P O Magner
Journal:  Arch Neurol       Date:  1984-04

4.  Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.

Authors:  J Tack; S J Middleton; M C Horne; H Piessevaux; J S Bloor; N L Meyers; R M J Palmer
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

5.  Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.

Authors:  C E J Sloots; A C Poen; R Kerstens; M Stevens; M De Pauw; J C Van Oene; S G M Meuwissen; R J F Felt-Bersma
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

6.  Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.

Authors:  A M George; N L Meyers; R I Hickling
Journal:  Aliment Pharmacol Ther       Date:  2008-02-14       Impact factor: 8.171

7.  Pilot study on the effect of linaclotide in patients with chronic constipation.

Authors:  Jeffrey M Johnston; Caroline B Kurtz; Douglas A Drossman; Anthony J Lembo; Brenda I Jeglinski; James E MacDougall; Stephen M Antonelli; Mark G Currie
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

8.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Authors:  Viola Andresen; Michael Camilleri; Irene A Busciglio; April Grudell; Duane Burton; Sanna McKinzie; Amy Foxx-Orenstein; Caroline B Kurtz; Vineeta Sharma; Jeffrey M Johnston; Mark G Currie; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2007-07-03       Impact factor: 22.682

9.  Tardive dyskinesia and diabetes mellitus.

Authors:  L Ganzini; D E Casey; W F Hoffman; R T Heintz
Journal:  Psychopharmacol Bull       Date:  1992

10.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

Authors:  L Ganzini; D E Casey; W F Hoffman; A L McCall
Journal:  Arch Intern Med       Date:  1993-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.